ORI-INDUSTRIES
4.10.2021 07:02:05 CEST | Business Wire | Press release
London based edge computing pioneer Ori Industries is partnering with VMware, Inc. (NYSE: VMW), a leading innovator in enterprise software, to facilitate enterprise implementation of edge computing across hybrid, telco and multi-cloud deployments. The interoperability of VMware Telco Cloud Platform and Ori Global Edge reduces complexity, increases service velocity, and manageability of cloud-native service delivery at the edge.
According to Gartner 1 , “edge computing is entering the mainstream”; however, many enterprises struggle with their existing cloud deployments proving to be a barrier to edge adoption. Ori and VMware’s partnership will help overcome this challenge by offering a fully functioning edge platform that connects to any cloud environment from telco to hybrid to multi-cloud.
Ori Global Edge on VMware Telco Cloud Platform is a managed cloud service offering that delivers a multi-connected edge by using multiple points of presence (PoP) that connect to the telco and communications service provider (CSP) infrastructure on one end and different clouds on the other end. The solution2 enables CSPs to offer multi-access edge computing (MEC) capabilities, which allow them to greater monetize their 5G offering to the enterprise. At the same time, it allows them to reduce their backhaul costs through intelligent workload placement.
Customers will benefit from service availability at the edge with low latency, highly-available applications generating and processing data locally without overhead for data transfer back to the cloud for processing. Extracting, analysing and using data at the edge permits a new class of enterprise services for enhanced customer experience.
Stephen Spellicy , vice president of product marketing, Service Provider and Edge, VMware, said, “Enterprises are looking for new ways to engage customers and deliver next-generation experiences. That means having the right application deployed where the user is. Edge computing is the final piece of the puzzle and working with Ori Industries’ multi-access edge computing platform will give mutual customers the ability to deploy a solution that helps cover all their environments – whether telco, hybrid, multi-cloud or edge – to meet their business needs.”
Douglas Mancini , CCO at Ori Industries said “Edge computing offers enterprises immense opportunities to not only deliver new innovative solutions but also reinvent their existing infrastructure in a more efficient way: Enterprises have learned that a pure cloud-first model has failed to deliver the expected value or agility, and Ori Global Edge is helping do just that. By combining our edge computing expertise with VMware Telco Cloud Platform and multi-cloud leadership, we are able to offer enterprises a way of harnessing the power of edge and reaping the benefits of being able to use data near to its creation.”3
For more information visit: https://ori.co/ .
About Ori Industries
Ori Industries is laying the foundation for the global rollout of edge computing services. The company’s edge platform simplifies workload provisioning across public, Telco, hybrid, and multi-cloud infrastructure to support countless new and emerging enterprise use cases. Ori Industries is based in London with a global workforce. For more information, please visit https://www.ori.co/ .
VMware and VMware Telco Cloud Platform are registered trademarks or trademarks of VMware, Inc. or its subsidiaries in the United States and other jurisdictions.
1
https://www.gartner.com/en/documents/3992656/2021-strategic-roadmap-for-edge-computing
2
Solution Overview: https://www.vmware.com/content/dam/digitalmarketing/vmware/en/pdf/microsites/telco/vmware-ori-solution-brief.pdf
3
Video Interview: https://www.youtube.com/watch?v=R-fUFNElWzo
View source version on businesswire.com: https://www.businesswire.com/news/home/20211003005023/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom